FDA grants Genentech's Perjeta regimen accelerated approval


Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration granted accelerated approval of a Perjeta regimen for neoadjuvant treatment in people with high-risk, HER2-positive early stage breast cancer. The Perjeta regimen is the first neoadjuvant breast cancer treatment approved by the FDA and also the first to be approved based on pCR data.

View Comments (0)